Histological Chorioamnionitis and Funisitis as New Risk Factors for Retinopathy of Prematurity: A Meta-analysis
American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e3264-e3273
DOI: 10.1055/a-2215-0662 ↗Kurz gefasst
Metaanalyse in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Salma El Emrani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Chorioamnionitis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ODAS Foundation.
Abstract (Originalsprache)
Objective
The role of placental inflammation in neonatal morbidities is underestimated due to lack of placental examination. This meta-analysis aims to assess the association between histological chorioamnionitis (HCA) with and without funisitis (FUN) and risk of retinopathy of prematurity (ROP). Study Design Forty-five studies reporting (unadjusted) data on HCA without FUN and HCA with FUN in neonates with ROP were included. Primary outcomes were any stage ROP and severe ROP. Potential confounders explored were gestational age (GA) at birth, birthweight, maternal steroid use, necrotizing enterocolitis, sepsis (suspected/proven) and mechanical ventilation duration.
Results
Neonates with HCA had increased risk for any stage ROP (odds ratio [OR] 1.8; 95% confidence interval [CI] 1.3–2.4) and severe ROP (OR 1.5; 95% CI 1.2–1.8) compared with neonates without HCA. The rates of any stage ROP (OR 1.8; 95% CI 1.4–2.2) and severe ROP (OR 1.4; 95% CI 1.1–1.6) were higher in neonates with FUN compared with neonates without FUN. Multivariate meta-regression analysis suggests that lower GA increases the effect size between FUN and severe ROP.
Conclusion
This meta-analysis confirms that presence of HCA and FUN are risk factors for any stage ROP and severe ROP. Structured histological placental examination of HCA and FUN may be a tool to further refine the ROP risk profile. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
- Division of Neonatology, Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.
- Division of Neonatology, Department of Women and Neonate, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
- Division of Medical Statistics, Department of Biomedical Data Science, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: Salma El Emrani
Förderung
- ODAS Foundation
Zitieren
APA
El Emrani, S., Jansen, E. J. S., Goeman, J. J., Lopriore, E., Termote, J. U. M., Schalij-Delfos, N. E., & van der Meeren, L. E. (2024). Histological Chorioamnionitis and Funisitis as New Risk Factors for Retinopathy of Prematurity: A Meta-analysis. American Journal of Perinatology, 41(S 01 S 01), e3264-e3273. https://doi.org/10.1055/a-2215-0662
Vancouver
El Emrani S, Jansen EJS, Goeman JJ, Lopriore E, Termote JUM, Schalij-Delfos NE, et al. Histological Chorioamnionitis and Funisitis as New Risk Factors for Retinopathy of Prematurity: A Meta-analysis. American Journal of Perinatology. 2024;41(S 01 S 01):e3264-e3273. doi:10.1055/a-2215-0662
BibTeX
@article{ElEmrani2024,
author = {El Emrani, Salma and Jansen, Esther J S and Goeman, Jelle J and Lopriore, Enrico and Termote, Jacqueline U M and Schalij-Delfos, Nicoline E and van der Meeren, Lotte E},
title = {Histological Chorioamnionitis and Funisitis as New Risk Factors for Retinopathy of Prematurity: A Meta-analysis},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {S 01 S 01},
pages = {e3264--e3273},
doi = {10.1055/a-2215-0662}
}
EUVIMED